[go: up one dir, main page]

DK2376116T3 - Anti-IGF-antistoffer. - Google Patents

Anti-IGF-antistoffer. Download PDF

Info

Publication number
DK2376116T3
DK2376116T3 DK09771361.4T DK09771361T DK2376116T3 DK 2376116 T3 DK2376116 T3 DK 2376116T3 DK 09771361 T DK09771361 T DK 09771361T DK 2376116 T3 DK2376116 T3 DK 2376116T3
Authority
DK
Denmark
Prior art keywords
igf
ser
val
thr
gly
Prior art date
Application number
DK09771361.4T
Other languages
English (en)
Inventor
Paul Adam
Eric Borges
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40512371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2376116(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK2376116T3 publication Critical patent/DK2376116T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (31)

1. Isoleret humant antistofmolekyle, hvilket a) binder til human IGF-1 og IGF-2 således at i) binding af IGF-1 og IGF-2 til IGF-l-receptoren hindres og ii) IGF-l-receptor-medieret signalering inhiberes, b) binder til muse- og rotte-IGF-1 og -IGF-2, c) ikke binder til humant insulin; hvor antistofmolekylet er et antistofmolekyle, som har tung-kæde-CDR'er omfattende ami-nosyresekvenserne ifølge SEQ ID NO:21 (CDR1), SEQ ID NO:22 (CDR2) og SEQ ID NO:23 (CDR3), og som har let-kæde-CDR'er omfattende aminosyresekvenserne ifølge SEQ ID NO:24 (CDR1), SEQ ID NO:25 (CDR2) og SEQ ID NO:26 (CDR3).
2. Antistofmolekyle ifølge krav 1, hvilket har en variabel tung kæde omfattende aminosyresekvensen ifølge SEQ ID NO:28.
3. Antistofmolekyle ifølge krav 1, hvilket har en variabel let kæde omfattende aminosyresekvensen ifølge SEQ ID NO:30.
4. Antistofmolekyle ifølge et hvilket som helst af kravene 1 til 3, omfattende en tung-kæde-konstant-region valgt fra gruppen bestående af IgGl-, IgG2-, IgG3-, IgG4-, IgM-, IgA- og IgE-konstante regioner.
5. Antistofmolekyle ifølge krav 4, hvor tung-kæde-konstant-regionen er IgGl omfattende aminosyresekvensen ifølge SEQ ID NO:32.
6. Antistofmolekyle ifølge et hvilket som helst af kravene 1 til 3, hvor let-kæde-konstant-regionen er IgA.
7. Antistofmolekyle ifølge krav 6, hvor let-kæde-konstant-regionen omfatter aminosyresekvensen ifølge SEQ ID NO:34.
8. Antistofmolekyle ifølge krav 2 eller 3, hvilket har a) en tung kæde omfattende aminosyresekvensen ifølge SEQ ID NO:39 og b) en let kæde omfattende aminosyresekvensen ifølge SEQ ID NO:40.
9. Antistofmolekyle ifølge et hvilket som helst af kravene 1 til 3, hvilket er et Fab-, F(ab’)2- eller enkeltkæde Fv-fragment.
10. DNA-molekyle kodende for den variable tunge kæde og den variable lette kæde af et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 9.
11. DNA-molekyle ifølge krav 10, hvilket har nucleotidsekvensen ifølge SEQ ID NO: 27, som koder for den variable tunge kæde af antistoffet defineret i krav 2, og hvilket har nucleotidsekvensen ifølge SEQ ID NO: 29, som koder for den variable lette kæde af antistoffet defineret i krav 3.
12. Ekspressionsvektor indeholdende et DNA-molekyle omfattende nucleotidsekvensen kodende for den variable tunge kæde og den variable lette kæde af et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 9.
13. Ekspressionsvektor ifølge krav 12 indeholdende et DNA-molekyle omfattende nucleotidsekvensen ifølge SEQ ID NO:27 og/eller SEQ ID NO:29.
14. Ekspressionsvektor ifølge krav 12 eller 13 yderligere omfattende et DNA-molekyle kodende for henholdsvis den konstante tunge kæde og/eller den konstante lette kæde, koblet til DNA-molekylet kodende for henholdsvis den variable tunge kæde og/eller den variable lette kæde.
15. Værtscelle, som bærer én eller flere ekspressionsvektorer ifølge krav 12, 13 eller 14.
16. Værtscelle ifølge krav 15, hvilken er en mammal celle.
17. Fremgangsmåde til fremstilling af et antistof ifølge et hvilket som helst af kravene 1 til 9, omfattende transfektion af en mammal værtscelle med én eller flere vektorer ifølge krav 12 til 14, dyrkning af værtscellen og indvinding og oprensning af antistoffet.
18. Fremgangsmåde til fremstilling af et antistof ifølge et hvilket som helst af kravene 1 til 9, omfattende tilvejebringelse af en mammal værtscelle omfattende én eller flere vektorer ifølge krav 12 til 14 og dyrkning af værtscellen.
19. Fremgangsmåde ifølge krav 18 yderligere omfattende indvinding og oprensning af antistoffet.
20. Antistofmolekyle ifølge et hvilket som helst af kravene 1 til 9 til anvendelse i medicin.
21. Antistofmolekyle ifølge et hvilket som helst af kravene 1 til 9 til anvendelse i behandling af en cancersygdom valgt blandt cancere af det hæmatopoietiske system omfattende leukæmier, lymphomer og myelomer, cancere af gastrointestinalkanalen omfattende øsophageal, gastrisk, colorectal, pancreatisk, lever- og galdeblærecancer og galdevejscancer, især hepatocellulært carcinom; nyre-, prostata- og blærecancer; gynækologiske cancere omfattende bryst-, ovarie-, cervix- og endometriecancer; hud- og hoved- og halscancere omfattende maligne melanomer; pædiatriske cancere såsom Wilms' tumor, neuroblastom og Ewings sarcom; hjernecancere såsom glioblastom; sarcomer såsom osteosarcom, bløddelssarcom, rhabdomyosarcom, hæmangiosarcom; lungecancer, især ikke-småcellet lungecancer; mesotheliom og thyreoideacancer.
22. Antistofmolekyle ifølge krav 21, hvor medikamentet er til anvendelse i kombination med platin-baseret kemoterapi, især paclitaxel/carboplatin eller gemcitabin/cisplatin platin-dublet-terapi, sorafenib eller en forbindelse valgt fra gruppen af inhibitorer af EGFR, VEGF, FIER2-neu, AuroraB, Plkl, PI3-kinase eller mTor.
23. Antistofmolekyle ifølge krav 22, hvor inhibitoren af mTor er rapamycin, temsi-rolimus, deforolimus eller everolimus.
24. Farmaceutisk sammensætning omfattende et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 9 og et farmaceutisk acceptabelt bærestof.
25. Farmaceutisk sammensætning ifølge krav 24 yderligere omfattende ét eller flere yderligere terapeutiske midler valgt blandt a) DNA-skadende midler, b) terapeutisk aktive forbindelser, som inhiberer signaltransduktionsveje eller mito-tiske checkpoints i cancerceller, c) antidiabetiske midler.
26. Farmaceutisk sammensætning ifølge krav 25, hvor de én eller flere forbindelser b) er valgt fra gruppen af inhibitorer af EGFR, VEGF, FIER2-neu, AuroraB, PI kl, PI3-kinase eller mTor.
27. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 24 til 26 til anvendelse i behandling af en cancersygdom valgt blandt cancere af det hæmatopoietiske system omfattende leukæmier, lymphomer og myelomer, cancere af gastrointestinalkana-len omfattende øsophageal, gastrisk, colorectal, pancreatisk, lever- og galdeblærecancer og galdevejscancer, især hepatocellulært carcinom; nyre-, prostata- og blærecancer; gynækologiske cancere omfattende bryst-, ovarie-, cervix- og endometriecancer; hud- og hoved- og halscancere omfattende maligne melanomer; pædiatriske cancere såsom Wilms' tumor, neuroblastom og Ewings sarcom; hjernecancere såsom glioblastom; sarcomer såsom osteosarcom, bløddelssarcom, rhabdomyosarcom, hæmangiosarcom; lungecancer, især ikke-småcellet lungecancer; mesotheliom og thyreoideacancer.
28. Farmaceutisk sammensætning ifølge krav 27 til yderligere anvendelse i kombination med platin-baseret kemoterapi, især paclitaxel/carboplatin eller gemcitabin/cisplatin platin-dublet-terapi, sorafenib eller en forbindelse valgt fra gruppen af inhibitorer af EGFR, VEGF, FIER2-neu, AuroraB, Plkl, PI3-kinase eller mTor.
29. In v/'tro-fremgangsmåde til inhibering af bindingen af IGF-1 og IGF-2 til IGF-1-receptoren i en mammal celle, omfattende indgift til cellen af et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 9, hvorved signalering medieret af IGF-l-receptoren og proliferation og anti-apoptose medieret af IGF-1 og IGF-2 inhiberes.
30. In v/'tro-fremgangsmåde til inhibering af bindingen af IGF-2 til insulinreceptoren IR-A i en mammal celle, omfattende indgift til cellen af et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 9, hvorved signalering medieret af insulinreceptoren IR-A inhiberes, og hvorved proliferation og anti-apoptose medieret af IGF-2 inhiberes.
31. In v/'tro-fremgangsmåde til monitorering af virksomheden af en behandling af en cancerpatient med et antistofmolekyle, som binder til IGF-1 og IGF-2, hvor antistofmolekylet er et antistofmolekyle ifølge et hvilket som helst af kravene 1 til 9, hvor fremgangsmåden omfatter (a) måling, i en biologisk prøve fra patienten, af niveauet af samlet IGF-1, (b) måling, i en biologisk prøve fra patienten, af niveauet af samlet IGF-1 efter indgift til patienten af anti-IGF-antistofmolekylet, hvor mængden af øgning i niveauet af samlet IGF-1, sammenlignet med niveauet af samlet IGF-1 målt i trin (a), indikerer i hvilket omfang patienten responder på behandling med anti-IGF-antistofmolekylet.
DK09771361.4T 2008-12-12 2009-12-11 Anti-IGF-antistoffer. DK2376116T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08171554 2008-12-12
PCT/EP2009/066894 WO2010066868A2 (en) 2008-12-12 2009-12-11 Anti-igf antibodies

Publications (1)

Publication Number Publication Date
DK2376116T3 true DK2376116T3 (da) 2016-02-29

Family

ID=40512371

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09771361.4T DK2376116T3 (da) 2008-12-12 2009-12-11 Anti-IGF-antistoffer.

Country Status (38)

Country Link
US (4) US8318159B2 (da)
EP (2) EP3064219A3 (da)
JP (2) JP5694184B2 (da)
KR (1) KR101827332B1 (da)
CN (3) CN103396487A (da)
AP (1) AP3371A (da)
AR (1) AR074726A1 (da)
AU (1) AU2009324296B2 (da)
BR (1) BRPI0923359B8 (da)
CA (1) CA2740341C (da)
CL (1) CL2011001431A1 (da)
CO (1) CO6390042A2 (da)
CY (1) CY1117241T1 (da)
DK (1) DK2376116T3 (da)
EA (1) EA029178B1 (da)
EC (1) ECSP11011126A (da)
ES (1) ES2561045T3 (da)
GE (1) GEP20146119B (da)
HR (1) HRP20160190T1 (da)
HU (1) HUE026374T2 (da)
IL (1) IL212047A (da)
MA (1) MA32888B1 (da)
ME (1) ME02377B (da)
MX (1) MX2011006055A (da)
MY (1) MY150984A (da)
NZ (3) NZ597692A (da)
PE (1) PE20120415A1 (da)
PL (1) PL2376116T3 (da)
PT (1) PT2376116E (da)
RS (1) RS54423B1 (da)
SG (2) SG2014013841A (da)
SI (1) SI2376116T1 (da)
TN (1) TN2011000299A1 (da)
TW (1) TWI471139B (da)
UA (1) UA105198C2 (da)
UY (1) UY32317A (da)
WO (1) WO2010066868A2 (da)
ZA (1) ZA201102308B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
ES2537580T3 (es) 2007-09-04 2015-06-09 Compugen Ltd. Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
NZ591918A (en) 2008-11-10 2012-08-31 Novartis Ag Antibodies to modified human igf-1/e peptides
CN103396487A (zh) 2008-12-12 2013-11-20 贝林格尔.英格海姆国际有限公司 抗igf抗体
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
WO2011053779A2 (en) * 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2640421A4 (en) * 2010-11-16 2014-05-28 Medimmune Llc THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
EP2726503B1 (en) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
HRP20190044T1 (hr) * 2011-09-23 2019-02-22 Oncomed Pharmaceuticals, Inc. Agensi koji vežu vegf/dll4 i njihove uporabe
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
TW201427685A (zh) * 2012-09-25 2014-07-16 Biogen Idec Inc Ｆｉｘ多肽的應用
CN102863530A (zh) * 2012-09-26 2013-01-09 李彬 一种脂肪细胞分化代谢产物igf-1抗体及包含该抗体的芯片以及应用
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
JP2016528167A (ja) 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒトＦｃＲｎ結合改変抗体及び使用方法
KR102266819B1 (ko) 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
SG11201603028SA (en) * 2013-10-18 2016-05-30 Universität Für Bodenkultur Wien Purification of proteins
JP2017502025A (ja) * 2013-12-19 2017-01-19 メディミューン，エルエルシー 肉腫を治療するための組成物および方法
RU2698969C2 (ru) 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
HRP20192260T1 (hr) * 2014-01-24 2020-03-06 Boehringer Ingelheim International Gmbh Liječenje raka uporabom antagonista receptora faktora rasta nalik inzulinu (igf) u kombinaciji s eksemestanom i everolimusom
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
US20180104332A1 (en) * 2015-01-16 2018-04-19 The University Of Liverpool Insulin-like growth factor inhibitor and chemotherapeutic agent for use in cancer therapy
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
US20170088609A1 (en) 2015-09-28 2017-03-30 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN105622730B (zh) * 2016-02-18 2020-06-26 深圳华尔康生物科技有限公司 一种特异性结合igf-1的多肽及其应用
EP3878850A1 (en) 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
US20200239559A1 (en) 2017-09-29 2020-07-30 Boehringer Ingelheim International Gmbh Anti igf, anti pd-1, anti-cancer combination therapy
CN116731173A (zh) 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
PH12020550786A1 (en) 2017-12-21 2021-04-12 Boehringer Ingelheim Int Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
KR102404684B1 (ko) * 2019-01-15 2022-06-07 서울대학교산학협력단 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
KR20230019462A (ko) 2020-06-02 2023-02-08 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
CN115232108B (zh) 2021-04-23 2025-04-18 领泰生物医药(绍兴)有限公司 Sos1降解剂及其制备方法和应用
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250145608A1 (en) 2021-12-01 2025-05-08 Boehringer Ingelheim Int'l GmbH Corp. Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
EP4441056A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099612A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CR20240233A (es) 2021-12-01 2024-07-17 Univ Vanderbilt Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
CN114671949B (zh) * 2022-04-20 2023-04-28 山西农业大学 一种igf1纳米抗体及其应用
JP2025517443A (ja) * 2022-05-20 2025-06-05 レゾリュート インコーポレイテッド 抗インスリン受容体抗体のための製剤及びそれらの使用
KR20240053520A (ko) * 2022-10-14 2024-04-24 포항공과대학교 산학협력단 Igf-1 수용체 결합 압타머 및 이의 용도
JP2025536369A (ja) 2022-10-21 2025-11-05 リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用
WO2024083256A1 (zh) 2022-10-21 2024-04-25 上海领泰生物医药科技有限公司 pan-KRAS降解剂及其制备方法和应用
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025210041A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Bicyclic benzylamido pyridine derivatives as sos1 inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
ATE220101T1 (de) 1983-04-25 2002-07-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinähnlichen wachstumsfaktoren
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
AU1232188A (en) 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
DE68927854T2 (de) 1988-06-30 1997-10-16 Hope City Insulinomimetrische eigenschaften und insulin-rezeptor-bindestellen-peptide
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
EP0700994A1 (en) 1994-03-23 1996-03-13 Japan Clinical Laboratories Anti-igf-i monoclonal antibody
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1034188B1 (en) 1997-11-27 2006-06-07 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor (1-462)
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
AR032028A1 (es) 2001-01-05 2003-10-22 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
NZ527591A (en) 2001-01-17 2006-04-28 Trubion Pharmaceuticals Inc Binding domain-immunoglobulin fusion proteins
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
DK1461359T3 (da) 2002-01-18 2007-07-09 Pf Medicament Hidtil ukendte anti-IGF-IR-antistoffer og anvendelser deraf
JP2003310275A (ja) 2002-04-30 2003-11-05 Kyowa Hakko Kogyo Co Ltd ヒトインスリン様成長因子に対する遺伝子組換え抗体
AU2003231554A1 (en) 2002-04-30 2003-11-17 Kyowa Hakko Kogyo Co., Ltd. Antibody to human insulin-like growth factor
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US20030138430A1 (en) * 2002-09-20 2003-07-24 Stimmel Julie Beth Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
AU2004212344B2 (en) 2003-02-13 2009-05-07 Pfizer Products Inc. Uses of anti-insulin-like growth factor I receptor antibodies
EP1603948A1 (en) 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
WO2005018671A1 (ja) 2003-08-21 2005-03-03 Kyowa Hakko Kogyo Co., Ltd. 癌転移阻害剤
EP1671647A1 (en) 2003-09-24 2006-06-21 Kyowa Hakko Kogyo Co., Ltd. Medicament for treating cancer
US7498415B2 (en) 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
BRPI0513200A (pt) 2004-07-16 2008-04-29 Pfizer Prod Inc uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
AR053489A1 (es) 2005-05-24 2007-05-09 Morphosys Ag Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
JP5362359B2 (ja) * 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
US7939637B2 (en) 2005-12-13 2011-05-10 Medimmune Limited Insulin-like growth factor antibodies and uses thereof
WO2007092453A2 (en) 2006-02-03 2007-08-16 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
SG170799A1 (en) 2006-03-28 2011-05-30 Biogen Idec Inc Anti-igf-ir antibodies and uses thereof
MX2008012754A (es) * 2006-04-07 2009-04-27 Us Gov Health & Human Serv Composiciones de anticuerpos y metodos para tratamiento de enfermedad neoplastica.
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
EP2027470B1 (en) 2006-06-02 2012-11-21 Pfizer Products Inc. Circulating tumor cell assay
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
WO2008079324A1 (en) 2006-12-21 2008-07-03 Boston Biomedical Research Institute Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
GB0702888D0 (en) 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
US20100166747A1 (en) 2007-03-02 2010-07-01 Beltran Pedro J Methods and compositions for treating tumor diseases
WO2008115470A2 (en) 2007-03-16 2008-09-25 East Carolina University Hox-gene expression as a biomarker for igf-1r therapeutics
UA96473C2 (ru) 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
US8492328B2 (en) 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2008152422A2 (en) 2007-06-12 2008-12-18 Astrazeneca Ab Binding proteins specific for insulin-like growth factors and uses thereof-909
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
WO2009006336A1 (en) 2007-06-28 2009-01-08 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
AU2008282863A1 (en) 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2009016164A1 (en) 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
WO2009019117A1 (en) 2007-08-03 2009-02-12 Affibody Ab Igf-1r binding polypeptides and their use
ES2453108T3 (es) 2007-08-06 2014-04-04 Orion Genomics, Llc Nuevos polimorfismos de un único nucleótido y combinaciones de polimorfismos nuevos y conocidos para determinar la expresión específica de alelo del gen IGF2
CN101842117A (zh) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 抗igf-1r抗体及其用途
CN101842116A (zh) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 结合igf-1r多个表位的组合物
CN101990577A (zh) 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
CA2694356A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2008307634A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
EP2247757A2 (en) 2007-12-18 2010-11-10 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
US20090258365A1 (en) 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
WO2009126304A1 (en) 2008-04-11 2009-10-15 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds
MX2010012064A (es) 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
WO2009137758A2 (en) 2008-05-09 2009-11-12 Dyax Corp. Igf-ii/gf-iie binding proteins
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN102164960A (zh) 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
JP2012503487A (ja) 2008-09-26 2012-02-09 シェーリング コーポレイション 高力価抗体の製造
WO2010045315A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
WO2010048123A2 (en) 2008-10-20 2010-04-29 Eckhardt S Gail Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
NZ591918A (en) 2008-11-10 2012-08-31 Novartis Ag Antibodies to modified human igf-1/e peptides
CN104398471A (zh) 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
CN103396487A (zh) 2008-12-12 2013-11-20 贝林格尔.英格海姆国际有限公司 抗igf抗体
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
AU2009329911A1 (en) 2008-12-23 2011-07-21 Salk Institute For Biological Studies Method of treating neurodegenerative disease
BRPI1015216A2 (pt) 2009-04-16 2016-04-12 Merck Sharp & Dohme método de tratar ou prevenir uma condição médica em um indivíduo.
WO2011057064A1 (en) 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
US20150056191A1 (en) 2012-03-30 2015-02-26 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
WO2013169611A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Compositions and methods for treating breast cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
HRP20192260T1 (hr) 2014-01-24 2020-03-06 Boehringer Ingelheim International Gmbh Liječenje raka uporabom antagonista receptora faktora rasta nalik inzulinu (igf) u kombinaciji s eksemestanom i everolimusom
US20170088609A1 (en) 2015-09-28 2017-03-30 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Also Published As

Publication number Publication date
PE20120415A1 (es) 2012-05-09
EP2376116B1 (en) 2015-12-09
AR074726A1 (es) 2011-02-09
GEP20146119B (en) 2014-07-25
CY1117241T1 (el) 2017-04-05
TWI471139B (zh) 2015-02-01
JP2015131812A (ja) 2015-07-23
US20150010574A1 (en) 2015-01-08
HUE026374T2 (en) 2016-05-30
CA2740341C (en) 2019-05-07
JP2012511315A (ja) 2012-05-24
AP3371A (en) 2015-07-31
CN102227226A (zh) 2011-10-26
RS54423B1 (sr) 2016-04-28
SG2014013841A (en) 2014-07-30
AU2009324296B2 (en) 2016-07-28
US8318159B2 (en) 2012-11-27
EP2376116A2 (en) 2011-10-19
CO6390042A2 (es) 2012-02-29
BRPI0923359B8 (pt) 2021-05-25
CA2740341A1 (en) 2010-06-17
EA201100918A1 (ru) 2012-01-30
CN103396488A (zh) 2013-11-20
IL212047A0 (en) 2011-06-30
US11299538B2 (en) 2022-04-12
EP3064219A2 (en) 2016-09-07
SI2376116T1 (sl) 2016-03-31
ES2561045T3 (es) 2016-02-24
WO2010066868A3 (en) 2010-09-10
WO2010066868A2 (en) 2010-06-17
UA105198C2 (ru) 2014-04-25
MY150984A (en) 2014-03-31
ZA201102308B (en) 2011-12-28
CN103396487A (zh) 2013-11-20
HRP20160190T1 (hr) 2016-03-25
ME02377B (me) 2016-06-20
CN102227226B (zh) 2015-05-13
SG172107A1 (en) 2011-07-28
NZ597694A (en) 2013-08-30
AP2011005719A0 (en) 2011-06-30
US20100150940A1 (en) 2010-06-17
KR101827332B1 (ko) 2018-02-09
MX2011006055A (es) 2011-07-04
UY32317A (es) 2010-07-30
TN2011000299A1 (en) 2012-12-17
NZ592151A (en) 2012-10-26
BRPI0923359A2 (pt) 2015-07-21
JP5694184B2 (ja) 2015-04-01
US10179810B2 (en) 2019-01-15
CL2011001431A1 (es) 2012-02-17
PL2376116T3 (pl) 2016-07-29
ECSP11011126A (es) 2011-07-29
KR20110094034A (ko) 2011-08-19
HK1158933A1 (zh) 2012-07-27
EA029178B1 (ru) 2018-02-28
US20130230541A1 (en) 2013-09-05
MA32888B1 (fr) 2011-12-01
AU2009324296A1 (en) 2010-06-17
EP3064219A3 (en) 2016-09-28
US20190225681A1 (en) 2019-07-25
NZ597692A (en) 2013-08-30
IL212047A (en) 2016-03-31
TW201026327A (en) 2010-07-16
BRPI0923359B1 (pt) 2020-09-15
PT2376116E (pt) 2016-02-24

Similar Documents

Publication Publication Date Title
US11299538B2 (en) Anti-IGF antibodies
US8580254B2 (en) Anti-IGF antibodies
PL215171B1 (pl) Przeciwcialo przeciw czynnikowi wzrostu nerwów (NGF) lub jego fragment, kompozycja farmaceutyczna, zestaw, sposób wytwarzania przeciwciala lub jego fragmentu, zastosowanie skutecznej ilosci antagonistycznego przeciwciala anty-NGF lub jego fragmentu, zastosowanie antagonistycznego przeciwciala anty-NGF lub jego fragmentu, izolowany polinukleotyd zawierajacy sekwencje nukleotydowa kodujaca przeciwcialo lub jego fragment, wektor oraz komórka gospodarza zawierajaca polinukleotyd
US20130122005A1 (en) Anticancer combination therapy
HK1191352A (en) Anti-igf antibodies
HK1191351A (en) Anti-igf antibodies
HK1158933B (en) Anti-igf antibodies
HK1121038A1 (en) Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
HK1121038B (en) Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same